# Peptides for Stretch Marks: What the Evidence Actually Shows

> A clinical look at copper peptides (GHK-Cu) and Matrixyl for striae distensae. No dedicated human trial exists for either — both grade D for stretch marks specifically, despite stronger data on other skin.

*Published 2026-07-01 · Updated 2026-07-01 · By Elena Soto, PharmD*

The short answer
There is **no dedicated human randomized controlled trial of any peptide** — copper peptides (GHK-Cu / copper tripeptide-1) or Matrixyl (palmitoyl pentapeptide-4) — for treating stretch marks, and the two most authoritative striae reviews do not mention peptides at all.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) For striae specifically, every peptide grades **D**; the case rests on mechanism, not on stretch-mark outcomes.

Peptides are marketed hard for stretch marks, but the evidence for that specific use is thin. This comparison reports what the published literature does and does not show about copper peptides and Matrixyl for striae distensae. It is informational and editorial content only — not medical advice, not a treatment protocol, and not a sourcing or buying guide. Dosing and formulation details are reported strictly as seen in the literature and cosmetic practice, for completeness. A functional, prevention-first lens frames the emphasis here, but it never overrides the sourced facts — and the facts for this condition are limited.

## Is there any human trial of peptides for stretch marks?

No. The single most important fact is an absence: there is no controlled human striae trial for any peptide. A 2017 systematic review of topical management of striae distensae catalogs tretinoin, *Centella asiatica*, hyaluronic acid, silicone, cocoa butter, olive oil and almond oil — and contains zero references to copper peptides, GHK-Cu, Matrixyl or matrikines.[1](https://peptidevox.com/#r1) A 2020 systematic review and network meta-analysis of 14 randomized trials across 651 patients evaluated lasers, radiofrequency, microneedling, platelet-rich plasma, carboxytherapy and tretinoin — but no peptide therapy was included, because none qualified.[2](https://peptidevox.com/#r2)

So every peptide claim for stretch marks rests on indirect inference. Peptides demonstrably stimulate dermal collagen in *other* contexts — photoaged facial skin, normal thigh skin, fibroblast culture — and because striae are fundamentally a collagen and elastin remodeling problem, the mechanism is plausible. Plausible is not proven. On the highest-quality evidence scale, both peptides here grade D for stretch marks specifically, even though each carries A-to-B-grade evidence for adjacent dermal endpoints that are not striae. A frequently cited "Ash et al. 2011, 12-week copper-peptide striae RCT" circulates on supplement-marketing sites; it could not be located in PubMed or the named journal and should be treated as unverified and likely fabricated. You can confirm this yourself by searching the trial registry at [ClinicalTrials.gov](https://clinicaltrials.gov/), where no completed peptide-for-striae efficacy trial appears.

## How could peptides help stretch marks in theory?

Stretch marks are a form of dermal scarring: the affected skin shows epidermal and dermal atrophy, disorganized and reduced collagen bundles, and fragmented, realigned elastin fibers.[1](https://peptidevox.com/#r1) Most striae treatments — topical, procedural or otherwise — aim at the same target: driving fibroblasts to lay down new, better-organized collagen and elastin.[2](https://peptidevox.com/#r2) That is exactly the cellular machinery signal peptides and copper peptides act on, which is the entire basis for the untested hope that they could help.

Matrixyl is palmitoyl-KTTKS, a five-amino-acid fragment of the pro-collagen I C-terminal propeptide attached to a palmitic-acid tail. As a matrikine it mimics the breakdown signal of collagen, telling fibroblasts that matrix has been damaged and to synthesize more — upregulating collagen I, collagen III and IV, fibronectin and glycosaminoglycans while modestly restraining collagen-degrading enzymes.[7](https://peptidevox.com/#r7)[5](https://peptidevox.com/#r5) The palmitoyl tail exists because the bare KTTKS peptide is too hydrophilic to cross the stratum corneum; palmitoylation improves skin penetration by roughly 100-to-1,000-fold.[7](https://peptidevox.com/#r7) GHK-Cu, meanwhile, is a naturally occurring plasma tripeptide-copper complex that stimulates collagen synthesis, glycosaminoglycan and decorin production, and modulates the MMP/TIMP balance governing matrix turnover, alongside antioxidant and anti-inflammatory actions; gene-expression work shows GHK changes expression of roughly 31% of human genes by at least 50%.[3](https://peptidevox.com/#r3) The crucial caveat is that all of this is mechanism, documented on non-striae skin or in cell culture — none of it demonstrates that applying these peptides to a stretch mark measurably improves it in a controlled human trial.

## Which peptide has the stronger adjacent evidence?

For stretch marks specifically, neither wins — both grade D. But their off-label dermal evidence differs, and that is worth comparing honestly. Copper peptides edge ahead only because the closest human dermal-collagen study was generated on thigh skin, an anatomically striae-prone site, whereas Matrixyl's strongest human data are facial.

  Copper peptides vs Matrixyl for stretch marks

    DimensionCopper peptides (GHK-Cu)Matrixyl (Pal-KTTKS)

    Evidence for striaeNone (Grade D)None (Grade D)
    Best adjacent human dataThigh-skin procollagen rise, n=20 (Grade B)Facial anti-wrinkle RCT, n=93 (Grade A)
    Anatomical relevance of dataHigher (thigh, striae-prone site)Lower (facial photoaging)
    Mechanism fit for striaeCollagen + MMP/TIMP remodelingPro-collagen matrikine signal
    Topical safetyWell tolerated; patch-test if metal-sensitiveExcellent; judged non-sensitizing (CIR)

The most relevant human study of copper peptides is a one-month controlled trial in 20 healthy volunteers applying creams to the thighs; immunohistology showed a significant rise in procollagen synthesis in 7 of 10 volunteers using the copper-binding peptide cream — more than tretinoin (4/10), vitamin C (5/10) or melatonin (5/10).[4](https://peptidevox.com/#r4) This is an ultrastructural biomarker outcome on normal skin, not a stretch-mark clinical outcome, and the sample is tiny. A topical GHK-Cu gel is in registered study for acute skin-wound healing, again not striae.[8](https://peptidevox.com/#r8) Matrixyl's headline evidence is a 12-week, double-blind, placebo-controlled, split-face trial in 93 women aged 35 to 55, where 3 ppm Pal-KTTKS significantly reduced wrinkles and fine lines versus the vehicle moisturizer — strong data, but for facial photoaging, not stretch marks.[5](https://peptidevox.com/#r5)

What the evidence does NOT support
"Clinically proven to erase stretch marks" is false for any peptide.[1](https://peptidevox.com/#r1) Results in two to three weeks are implausible — even the supportive cosmetic trials ran 8 to 12 weeks.[5](https://peptidevox.com/#r5) And equal effect on old white striae albae and early red striae rubrae is unsupported; active treatments do better on early vascular striae, and there is no peptide data either way.[1](https://peptidevox.com/#r1)

## What is safe, and what actually works better?

Both peptides are sold as cosmetic skin-conditioning ingredients, not FDA-approved drugs, so neither is approved to treat or prevent stretch marks and neither has undergone drug-level efficacy review. Palmitoyl pentapeptide-4 was judged safe in cosmetics by the Cosmetic Ingredient Review Expert Panel in 2024 and predicted non-sensitizing in OECD assays, with minimal systemic absorption.[6](https://peptidevox.com/#r6) GHK-Cu is generally well tolerated topically because the copper's redox activity is quenched by the peptide; transient redness or tingling can occur, allergic contact dermatitis is rare but possible, and people with Wilson's disease should avoid added copper.[3](https://peptidevox.com/#r3) Striae frequently arise in pregnancy, and pregnancy-specific safety data for these peptides are not established — do not assume safety across ingredients, since topical tretinoin is contraindicated in pregnancy; consult an obstetric or dermatology clinician.[1](https://peptidevox.com/#r1)

**Bottom line.** If any peptide helps striae at all, it is most likely as a collagen-supporting adjunct on early red or purple striae rubrae, which are still biologically active, rather than mature white striae albae. But the better-evidenced topical for rubrae is tretinoin, hyaluronic acid and *Centella asiatica* have the prevention data, and the highest-ranked treatments overall in the comparative literature are procedural — bipolar radiofrequency, fractional CO2 laser and microneedling.[2](https://peptidevox.com/#r2)[1](https://peptidevox.com/#r1) Peptides sit in the plausible-but-unproven tier for this condition. This is not a reason to buy, compound or inject peptides for stretch marks — the evidence base does not support a peptide as a stretch-mark treatment. Facts here are current as of June 2026.

---
Source: https://peptidevox.com/skin-hair-aesthetic/peptides-for-stretch-marks
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt